Clinical aspects of transfusional iron overload

Reviews in Clinical and Experimental Hematology

Volumn 4, Issue 4, 2000, Pages 322-336

  Wonke, Beatrix ^a   De Sanctis, Vincenzo ^a  

^a WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; IRON CHELATING AGENT;

CARBOHYDRATE METABOLISM; DEVELOPED COUNTRY; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; ENDOCRINE DISEASE; GROWTH DISORDER; HEART DISEASE; HUMAN; IRON OVERLOAD; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SEXUAL DEVELOPMENT; SURVIVAL; THALASSEMIA MAJOR; THYROID DISEASE;

EID: 0034583927     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2000.00023.x     Document Type: Review

References (94)

1. Survival in β thalassaemia major in the UK. Data from the UK Thalassaemia Register
2. Growth of children with thalassaemia: Effect of different transfusion regimens
3. Growth and sexual maturation in thalassaemia major
4. Growth and development in children with thalassaemia major
5. Growth in thalassaemia major
6. Relationship of endocrinopathy to iron chelation states in young patients with thalassaemia major
7. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine
8. Growth failure and bony changes induced by deferoxamine
9. Deferoxamine-induced growth retardation in patients with thalassaemia major
10. Impiego a lungo termine della desferrioxamine ed effetti collaterali
11. Desferrioxamine-induced bone dysplasia in patients with thalassaemia major
12. Multicentre study on prevalence of endocrine complications in thalassaemia major
13. Short stature and failure of pubertal development in thalassaemia major: Evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotrophin secretion
14. Impaired growth hormone (GH) response to GH-releasing hormone in thalassaemia major
15. Depressed serum somatomedin activity in β thalassaemia
16. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine
17. Acute metabolic effect of human growth hormone on 15N-nitrogen balance in patients with thalassaemia-As compared to patients with other types of short stature
18. Growth in homozygous β thalassaemia patients
19. Neurosecretory dysfunction of growth hormone secretion in thalassaemia major
20. Growth and management of short stature in thalassaemia major
21. GH secretion in thalassaemia patients with short stature
22. Studies on the possible mechanism for deficiency of non-suppressible insulin-like activity in thalassaemia major
23. Short stature and body proportions in thalassaemia
24. 3 syndrome in thalassaemia major
25. Endocrine complications in thalassaemia major
26. Endocrine function in thalassaemia major
27. Hormonal changes in thalassaemia major
28. Growth, skeletal maturation and thyroid function in children with homozygous β thalassaemia
29. Gonadotrophin, thyrotropin and prolactin reserve in β thalassaemia
30. Thyroid function in thalassaemia major
31. Endocrine function in multi-transfused pre-pubertal patients with homozygous β thalassaemia
32. Endocrine involvement in children with β thalassaemia. Transverse and longitudinal studies. Pituitary thyroidal function and its correlation with serum ferritin levels
33. Insulin resistance and hyperinsulinemia in patients with thalassaemia major treated by hypertransfusion
34. Glucose tolerance and chelation therapy in patients with thalassaemia major
35. Insulin dependent diabetes in thalassaemia
36. The development of diabetes mellitus and chronic liver disease in long-term chelated β thalassaemia patients
37. Prevalence of retinopathy in diabetic thalassaemic patients
38. Increased renal glucose threshold in thalassaemic patients with diabetes
39. HLA-A B, C, and DR antigen frequencies in relation to development of diabetes and variations in white cell antibody formation in highly transfused thalassaemia patients
40. Glucose disturbances and regulation with glibenclamide in thalassaemia
41. Endocrine evolution in thalassaemia major
42. Endocrine function in thalassemia major
43. Endocrinopathy in thalassaemia major
44. Endocrine abnormalities in thalassaemia major
45. Gonadotrophin insufficiency in patients with thalassaemia major
46. Endocrine assessment of hypogonadism in patients affected by thalassaemia major
47. Hypothalamic-pituitary-gonadal axis in thalassaemic patients with secondary amenorrhoea
48. Gonadal function in patients with β thalassaemia major
49. Differential iron deposition in the anterior pituitary and liver in homozygous β thalassaemia: Prediction of gonadal failure by magnetic resonance imaging
50. Effect of age at the start of iron chelation therapy on gonadal function in β thalassaemia major
51. Evolution of hypothalamic-pituitary function in patients with thalassaemia major
52. Endocrine abnormalities in thalassaemia
53. Induction of spermatogenesis in thalassaemia
54. Pregnancy management and outcomes in women with thalassaemia major
55. Preliminary observations about assisted reproduction in thalassaemia
56. Fertility in female patients with thalassaemia
57. Fertility in thalassaemia: The Greek experience
58. Endocrine function in thalassaemia major
59. Adrenal function in thalassaemia major following long-term treatment with multiple transfusions and chelation therapy
60. Cortisol metabolism in chronic liver disease
61. Fractures in thalassaemia
62. Bone disease in children with homozygous β thalassaemia
63. Bone disease in β thalassaemia major
64. Multicentre study on prevalence of fractures in transfusion-dependent thalassaemia patients
65. Abnormal bone metabolism in thalassaemia
66. High prevalence of low bone mass in thalassaemia major
67. Methods for bone density measurement
68. Effects of Calcitonin therapy on osteoporosis in patients with thalassaemia
69. Response to bisphosphonate therapy for osteoporosis in thalassaemia major
70. Iron in the heart. Etiology and clinical significance
71. Histochemical studies of the myocardium and conduction system in acquired iron storage disease
72. Pathology of the cardiac conduction system in hemochromatosis
73. Cardiac involvement in hemochromatosis
74. The heart in hemachromatosis
75. Oxygen toxicity, oxygen radicals, transition metals and disease
76. Lipid peroxidation in iron overloaded spleens
77. Heart cell in culture: A model of myocardial iron overload and chelation
78. Lipid peroxide formation in microsomes. The role of non-haem iron
79. Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid and alphatocopherol in iron-loaded rat myocardial cell cultures
80. Early left ventricular dysfunction and chelation therapy in thalassaemia major
81. Desferrioxamine to improve cardiac function in iron-loaded patients with thalassaemia major
82. Desferrioxamine improves left ventricular function in β thalassaemia
83. High incidence of cardiomyopathy in β thalassaemia patients receiving transfusion and iron chelation: Reversal by intensified chelation
84. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassaemia major
85. Rapid removal of excessive iron with daily, high dose intravenous chelation therapy
86. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload
87. Internal distribution of excess iron and sources of serum ferritin in patients with thalassaemia
88. Value of hepatic iron measurement of early haemochromatosis and determination of the critical iron level associated with fibrosis
89. Myocardial iron grading by endomyocardial biopsy. A clinicopathologic study on iron overloaded patients
90. Cardiac iron overload in thalassaemic patients. An endomyocardial biopsy study
91. Myocarditis in β thalassaemia major
92. Myocardial iron quantification using T2* magnetic resonance in thalassaemia
93. The unpredictability of cardiac iron deposition in homozygous β-thalassemia